Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer
FT affected nearly one in four patients with PDAC at a high-volume cancer center and was associated with worse QOL and medication nonadherence. Universal screening and interventions to reduce FT are warranted. Clinical trials investigating QOL as an end point must account for potential confounding due to FT.
Authors
- Alice C. Wei (ORCID: https://orcid.org/0000-0002-2505-959X)
- Joséphine Magnin (ORCID: https://orcid.org/0000-0003-0277-7641)
- Anna M. Varghese (ORCID: https://orcid.org/0000-0001-5426-0885)
- Hannah L. Kalvin (ORCID: https://orcid.org/0000-0002-6636-0602)
- William R. Jarnagin (ORCID: https://orcid.org/0000-0002-1635-5768)
- Lauren E. Schleimer (ORCID: https://orcid.org/0000-0002-5135-6694)
- Mithat Gönen (ORCID: https://orcid.org/0000-0001-8683-8477)
- Kevin C. Soares (ORCID: https://orcid.org/0000-0002-0406-017X)
- Stefania Sokolowski (ORCID: https://orcid.org/0000-0003-2642-5384)
- Emeline Aviki (ORCID: https://orcid.org/0000-0003-0891-9399)
- T. Peter Kingham (ORCID: https://orcid.org/0000-0002-3359-3186)
- Eileen Mary O'Reilly (ORCID: https://orcid.org/0000-0002-8076-9199)
- Jeffrey A. Drebin (ORCID: https://orcid.org/0000-0003-2312-2062)
- Bridgette Thom (ORCID: https://orcid.org/0000-0001-6239-1666)
- Michael I. D’Angelica
Institutions
- University of North Carolina at Chapel Hill (US)
- Memorial Sloan Kettering Cancer Center (US)
- NYU Langone Health (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1200/op-24-00528
- Citations
- 10
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 11.29
Funders
- AstraZeneca
- Genentech